WebOur growing pipeline of multifunctional gene and cell therapy candidates gives us distinct advantages for combination strategies. Our preclinical and clinical pipeline includes several programs leveraging our technologies in … WebApr 11, 2024 · In September 2024, Decibel Therapeutics announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration …
CGF166 Atonal Gene Therapy for Hearing Loss & Vestibular …
WebApr 11, 2024 · Bangkok - Singapore (BKK-SIN) International flight GF166 by Gulf Air serves route from Thailand to Singapore (BKK to SIN). The flight departs Bangkok, … WebCOMPLETED: Novartis Phase 1/2 Trial of CGF166, an Inner Ear Gene Therapy for Hearing Loss March 19, 2024 The status of study NCT02132130 (Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss), was changed from “Active, not recruiting” to “Completed” on March 19, 2024. pruning weeping cherry tree uk
COMPLETED: Novartis Phase 1/2 Trial of CGF166, an Inner Ear …
WebCGF166 Clinical Trials Update; CGF 166 Clears FDA Hurdle; The Search for a Cure; Tips. How to talk with someone who has hearing loss; Canadian Financial Assistance; Great … WebSep 19, 2024 · The goal of the current study is to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL-infusion to improve hearing and vestibular function. CGF166 is a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1). Estimated Enrollment: 45 WebJan 20, 2016 · The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. pruning weeping mulberry tree